Ticagrelor—a platelet aggregation inhibitor—gained FDA approval in February 2016 for use with low-dose acetylsalicylic acid (ASA) in adults who had suffered a myocardial infarction a year or more ago. However, its safety is now being calling into question.

The German Institute for Quality and Efficiency in Health Care found that adding ticagrelor to ASA drug therapy increased incidents of non-severe bleeding.

Furthermore, manufacturers were not able to produce data showing that quality of life increased with concurrent ticagrelor treatment.